Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications
Evaluating birth outcomes following oral rilpivirine use in pregnancy in the United States: Findings from the antiretroviral pregnancy registry.
Journal: HIV medicine
Published: June 25, 2025
Weight and Metabolic Changes With Long-Acting Cabotegravir and Rilpivirine or Bictegravir/Emtricitabine/Tenofovir Alafenamide.
Journal: Journal of acquired immune deficiency syndromes (1999)
Published: May 15, 2024
Cabotegravir + Rilpivirine Long-Acting: Overview of Injection Guidance, Injection Site Reactions, and Best Practices for Intramuscular Injection Administration.
Journal: Open forum infectious diseases
Published: February 21, 2024
Implementation of long-acting cabotegravir and rilpivirine: primary results from the perspective of staff study participants in the Cabotegravir And Rilpivirine Implementation Study in European Locations.
Journal: Journal of the International AIDS Society
Published: August 31, 2023
Efficacy, Safety, and Pharmacokinetics by Body Mass Index Category in Phase 3/3b Long-Acting Cabotegravir Plus Rilpivirine Trials.
Journal: The Journal of infectious diseases
Published: August 25, 2023
Economic burden of invasive Escherichia coli disease among older adult patients treated in hospitals in the United States.
Journal: Journal of managed care & specialty pharmacy
Published: July 31, 2023
Asian participants' experience in phase 3/3b studies of long-acting cabotegravir and rilpivirine: Efficacy, safety, pharmacokinetic, and virological outcomes through week 96.
Journal: HIV medicine
Published: July 06, 2023
Clinical burden of invasive Escherichia coli disease among older adult patients treated in hospitals in the United States.
Journal: BMC infectious diseases
Published: February 09, 2023
Pregnancy outcomes and pharmacokinetics in pregnant women living with HIV exposed to long-acting cabotegravir and rilpivirine in clinical trials.
Journal: HIV medicine
Published: July 20, 2022
Low Incidence and Brief Duration of Gastrointestinal Adverse Events with Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Over 96 Weeks: Post hoc Analyses of AMBER and EMERALD.
Journal: Journal of the International Association of Providers of AIDS Care
Published: April 25, 2022
Compassionate use of long-acting cabotegravir plus rilpivirine for people living with HIV-1 in need of parenteral antiretroviral therapy.
Journal: HIV medicine
Published: March 18, 2022
Week 96 subgroup analyses of the phase 3, randomized AMBER and EMERALD trials evaluating the efficacy and safety of the once daily darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) single-tablet regimen in antiretroviral treatment (ART)-naïve and -experienced, virologically-suppressed adults living with HIV-1.
Journal: HIV research & clinical practice
Published: February 02, 2021
Last Updated: 09/26/2026